ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1613

Circulating microRNAs As Candidate Biomarkers of Diagnosis in Systemic Lupus Erythematosus

Juyang Jung1, Ja-Young Jeon2, Bong-Sik Kim3, Hyoun-Ah Kim2 and Chang-Hee Suh4, 1Ajou university of medical school, Suwon, South Korea, 2Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea, 3Rheumatology, Ajou University School of Medicine, Suwon, South Korea, 4Rheumatology, Ajou University School of Med, Suwon, South Korea

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biomarkers and systemic lupus erythematosus (SLE), MicroRNA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Autoimmune Disease Transition, Disease Subsets and Prediction of Flares, Cytokines and Autoantibodies

Session Type: Abstract Submissions (ACR)

Background/Purpose :

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by polyclonal B-cell activation and elevated production of pathogenic autoantibodies. MicroRNAs (miRNAs) are short, noncoding RNAs that regulate gene expression on the posttranslational level, which can be measured in the circulation, and are emerging as novel biomarkers in various diseases. However, a systematic analysis of circulating miRNAs in SLE patients has been rarely addressed. We attempted to identify circulating miRNAs associated with the susceptibility to SLE in Korean populations, and to elucidate their significance in clinical phenotypes of SLE.

Methods:

Blood samples were collected from Korean SLE patients (n = 70) and normal controls (NC, n = 40) at the rheumatology clinic, Ajou University Hospital. The microRNA PCR arrays identified miRNAs differentially expressed in SLE patients and NC. For the microRNA PCR arrays, we isolated total RNA from plasma samples of 10 SLE patients and 10 NC. The RNAs were pooled in each sample group (n = 10) with an equal amount of RNAs. A miRNA expression profiling analysis was performed and compared between SLE patients and NC. To verify the microRNA PCR arrays results, we performed the quantitative real-time PCR in samples from SLE patients (n = 70) and NC (n = 40).

Results:

Nine miRNAs were differentially expressed in plasma between SLE patients and NC by miRNA PCR array. The plasma expression level of hsa-miR-17-5p, hsa-miR-19a-3p, hsa-miR-21-5p, hsa-miR-25-3p, hsa-miR-92a-3p, hsa-miR-223-3p, and hsa-miR-30e-5p were up-regulated in the SLE patients compared to the NC. The plasma expression level of hsa-miR-26b-5p and hsa-miR-150-5p were down-regulated in the SLE patients compared to the NC. The hsa-miR-30e-5p, hsa-miR-92a-3p, and hsa-miR-223-3p were significantly up-regulated in plasma from patients with SLE by quantitative real-time PCR. Especially, the hsa-miR-223-3p was significantly associated with oral ulcer (p<0.001) and lupus anticoagulant (p=0.031).

Conclusion: Our data suggest that plasma hsa-miR-30e-5p, hsa-miR-92a-3p and hsa-miR-223-3p may be novel important promising biomarkers in the diagnosis of SLE. These novel and promising markers warrant validation in larger prospective studies.


Disclosure:

J. Jung,
None;

J. Y. Jeon,
None;

B. S. Kim,
None;

H. A. Kim,
None;

C. H. Suh,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/circulating-micrornas-as-candidate-biomarkers-of-diagnosis-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology